Cytotoxic T lymphocyte mediated recognition of human pancreatic cancer cells

International Journal of Cancer

Volumn 99, Issue 1, 2002, Pages 88-92

  Peiper, Matthias ^a   Sato, Takeo ^a   Streichert, Thomas ^a   Eisenberger, Claus Ferdinand ^a   Knoefel, Wolfram Trudo ^a   Izbicki, Jakob Robert ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

CTL; HLA Class I; Immunotherapy; Pancreatic cancer

Indexed keywords

HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY W6 32; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; PANCREAS CANCER; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL LINE; CYTOTOXICITY TESTS, IMMUNOLOGIC; HLA ANTIGENS; HUMANS; PANCREATIC NEOPLASMS; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036568526     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10280     Document Type: Article

References (29)

1. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes and prognostic indicators
2. Innovative treatments for pancreatic cancer
3. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes
4. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/ neu-derived peptide
5. Activation of tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex
6. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-Class I restricted allogeneic cytotoxic T lymphocytes
7. Human tumor antigens recognized by T lymphocytes
8. Progress in human tumour immunology and immunotherapy
9. MHC ligands and peptide motifs: Fist listing
10. Induction of tumor-specific cytotoxic T lymphocytes from regional lymph node lymphocytes of human breast cancer
11. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw1601
12. Study of HLA Class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer
13. Lysis of human pancreatic adeno-carcinoma cells by autologous HLA-Class I-restricted cytolytic T-lymphocyte (CTL) clones
14. Lysis of a newly established human pancreatic cancer cell line by autologous tumor-infiltrating lymphocytes is ICAM-1 dependent
15. Autologous tumour-specific cytotoxic T cell clone established from tumour-infiltrating lymphocytes (TIL) of malignant ascites in the absence of recombinant interleukin 2 (rIL2): Activation by autologous tumour cell alone
16. A new human pancreatic cancer cell line (MPanc-96) recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion
17. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials
18. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer
19. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer
20. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients
21. From defined human tumor antigens to effective immunization
22. Purification of antigenic peptide from murine hepatoma cells recognized by Class-I major histocompatibility complex molecule-restricted cytotoxic T-lymphocytes induced with B7-1-gene-transfected hepatoma cells
23. 8+ cytotoxic T lymphocytes
24. TGF-β I pretreatment impairs the allostimulatory function of human bone marrow-derived antigen-presenting cells for both naive and primed T cells
25. Tumor cell lysate-pulsed human dendritic cells induce a T cell response against pancreatic carcinoma cells: An in vitro model for the assessment of tumor vaccines
26. Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells
27. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer
28. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a Phase II clinical trial
29. Immunization against epitopes in the human melanoma antigen gp1OO following patient immunization with synthetic peptides